ABUS Stock Analysis: Arbutus Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 982m USD | 12M Return: 65% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.90M
Qual. Beats: 1
Rev. Trend: 23.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a U.S.-based, clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious diseases, with a primary emphasis on chronic Hepatitis B virus (HBV). Its pipeline includes Imdusiran, a subcutaneously-delivered RNAi therapeutic in Phase 2a trials designed to suppress HBV antigens, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b trials aimed at reactivating HBV-specific immune response. The company also holds a licensing agreement with Alnylam Pharmaceuticals related to LNP delivery technology. Originally incorporated in 2005 as Tekmira Pharmaceuticals, Arbutus is headquartered in Warminster, Pennsylvania, and operates within the biotechnology sub-industry of the healthcare sector, where companies typically rely on partnerships, licensing deals, and capital markets to fund lengthy and costly drug development cycles before achieving commercialization.
- Imdusiran Phase 2a functional cure data readout approaches
- Alnylam LNP licensing royalty revenue declines post-pandemic
- HBV competitive landscape intensifies from Vir and GSK pipeline
| Net Income: 160.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA 38.06 > 1.0 |
| NWC/Revenue: 142.0% < 20% (prev 1.52k%; Δ -1.38k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -34.4m > Net Income 160.7m |
| Net Debt (-94.6m) to EBITDA (160.8m): -0.59 < 3 |
| Current Ratio: 54.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.2m) vs 12m ago 2.36% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 97.14% > 50% (prev 5.47%; Δ 91.67% > 0%) |
| Interest Coverage Ratio: 1.87k > 6 (EBIT TTM 160.8m / Interest Expense TTM 86.0k) |
| A: 0.98 (Total Current Assets 277.0m - Total Current Liabilities 5.11m) / Total Assets 277.2m |
| B: -4.37 (Retained Earnings -1.21b / Total Assets 277.2m) |
| C: 0.82 (EBIT TTM 160.8m / Avg Total Assets 197.1m) |
| D: 15.32 (Book Value of Equity 260.2m / Total Liabilities 17.0m) |
| Altman-Z'' = 13.76 = AAA |
| DSRI: 0.10 (Receivables 1.31m/1.18m, Revenue 191.4m/6.40m) |
| GMI: 0.78 (GM 78.45% / 99.98%) |
| AQI: 1.63 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 29.90 (Revenue 191.4m / 6.40m) |
| TATA: 0.70 (NI 160.7m - CFO -34.4m) / TA 277.2m) |
| Beneish M = 17.21 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 5.18 with a total of 5,088,657 shares traded. Over the past week, the price has changed by +10.68%, over one month by +22.17%, over three months by +16.14% and over the past year by +64.97%.
Current recommended Stop Loss: 4.90 (which is 5.4% or 1.5 ATR below the current price).
Arbutus Biopharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ABUS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.1 | -2.3% |
P/E Trailing = 5.988
P/E Forward = 10.2459
P/S = 5.1282
P/B = 3.6975
Revenue TTM = 191.4m USD
EBIT TTM = 160.8m USD
EBITDA TTM = 160.8m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 631k USD (from shortTermDebt, last quarter)
Debt = 631k USD (from shortLongTermDebtTotal, last quarter) (leases 631k already included)
Net Debt = -94.6m USD (calculated: Debt 631k - CCE 95.2m)
Enterprise Value = 887.2m USD (981.8m + Debt 631k - CCE 95.2m)
Interest Coverage Ratio = 1.87k (Ebit TTM 160.8m / Interest Expense TTM 86.0k)
EV/FCF = -25.82x (Enterprise Value 887.2m / FCF TTM -34.4m)
FCF Yield = -3.87% (FCF TTM -34.4m / Enterprise Value 887.2m)
FCF Margin = -17.95% (FCF TTM -34.4m / Revenue TTM 191.4m)
Net Margin = 83.95% (Net Income TTM 160.7m / Revenue TTM 191.4m)
Gross Margin = unknown ((Revenue TTM 191.4m - Cost of Revenue TTM 44.0k) / Revenue TTM)
Tobins Q-Ratio = 3.20 (Enterprise Value 887.2m / Total Assets 277.2m)
Interest Expense / Debt = 13.63% (Interest Expense 86.0k / Debt 631k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 127.0m (EBIT 160.8m * (1 - 21.00%))
Current Ratio = 54.26 (Total Current Assets 277.0m / Total Current Liabilities 5.11m)
Debt / Equity = 0.00 (Debt 631k / totalStockholderEquity, last quarter 260.2m)
Debt / EBITDA = -0.59 (Net Debt -94.6m / EBITDA 160.8m)
Debt / FCF = 2.75 (negative FCF - burning cash) (Net Debt -94.6m / FCF TTM -34.4m)
Total Stockholder Equity = 124.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 81.55% (Net Income 160.7m / Total Assets 277.2m)
RoE = 129.3% (Net Income TTM 160.7m / Total Stockholder Equity 124.3m)
RoCE = 129.4% (EBIT 160.8m / Capital Employed (Equity 124.3m + L.T.Debt 0.0))
RoIC = 48.28% (NOPAT 127.0m / Invested Capital 263.1m)
WACC = 9.27% (E(981.8m)/V(982.4m) * Re(9.27%) + D(631k)/V(982.4m) * Rd(13.63%) * (1-Tc(0.21)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 6.78%
[DCF] Fair Price = unknown (Cash Flow -34.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 23.21 | Revenue CAGR: 26.56% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.06 | Chg30d=+1.79% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=+1.79% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.22 | Chg30d=+3.52% | Revisions=+25% | GrowthEPS=+6.1% | GrowthRev=+1188.1%
EPS next Year (2027-12-31): EPS=-0.12 | Chg30d=N/A | Revisions=+25% | GrowthEPS=-112.0% | GrowthRev=-98.5%